Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma (PEGASE2)

Assistance Publique - Hôpitaux de Paris

Status: Active, not recruiting

Conditions: Asthma

Treatments: Drug: Salbutamol

Study type: Observational

Funder types: Other

Identifiers

NCT03592212

NI16014

Details and patient eligibility

About

This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.

Full description

Patients from 6 to 18 years old with asthma and receiving a treatment by salbutamol according to the usual care will be recruited. Saliva from patients will be collected using Oragen®.DNA OG-575 kit.

Enrollment: 99 patients

Sex: All

Ages: 6 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children 6-18 years
• Asthma: confirmed asthma symptoms (wheeze, cough, dyspnea, chest tightness) and evidence for variable airflow limitation (≥ 12% increase in post bronchodilator FEV1, or ≥ 20% decrease in FEV1 post methacholine)
• Spirometry prescribed for follow-up
• Airflow limitation: FEV1<80% and/or FEV1/FVC <80 pre-bronchodilator

Exclusion criteria

• no exclusion criteria